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Abstract
Background: The recent advances in human disease network have provided insights into establishing the
relationships between the genotypes and phenotypes of diseases. In spite of the great progress, it yet remains as
only a map of topologies between diseases, but not being able to be a pragmatic diagnostic/prognostic tool in
medicine. It can further evolve from a map to a translational tool if it equips with a function of scoring that
measures the likelihoods of the association between diseases. Then, a physician, when practicing on a patient, can
suggest several diseases that are highly likely to co-occur with a primary disease according to the scores. In this
study, we propose a method of implementing ‘n-of-1 utility’ (n potential diseases of one patient) to human disease
network—the translational disease network.
Results: We first construct a disease network by introducing the notion of walk in graph theory to protein-protein
interaction network, and then provide a scoring algorithm quantifying the likelihoods of disease co-occurrence given a
primary disease. Metabolic diseases, that are highly prevalent but have found only a few associations in previous
studies, are chosen as entries of the network.
Conclusions: The proposed method substantially increased connectivity between metabolic diseases and provided
scores of co-occurring diseases. The increase in connectivity turned the disease network info-richer. The result lifted
the AUC of random guessing up to 0.72 and appeared to be concordant with the existing literatures on disease
comorbidity.
Keywords: Semi-supervised learning, Disease network, Comorbidity, Protein interaction, Disease scoring
Background
The recent advances in human disease networks have
provided insights into establishing the relationships
between the genotypes and phenotypes of human dis-
eases [1–3]. A disease (or disorder) is often thought of
as resulting from rare mutations that trigger disruptions
in underlying cellular functions. However, it is far from
sufficient to define diseases solely by a mutation in a sin-
gle gene because they are influenced by the totality of
the intricate molecular connections between numerous
cellular components [4–7]. A series of successful experi-
ments developed in network biology have been beneficial
for the progress of human disease network analysis [8, 9],
which includes various types of molecular connections
such as networks of gene co-expression, transcriptional
regulations, protein interactions, metabolic pathways, and
so on [10]. In [11], the authors provide a good review on
the main features and the pros-cons of the existing meth-
ods for the disease-related biomolecular networks. Also, a
comprehensive compilation of known disease-disease
association can be found from many web services such as
the DiseaseConnect (http://disease-connect.org) [12].
An initiative challenge for human disease networks
was suggested by Goh et al. [13], which attempts to
identify disease associations based on the genes that dis-
eases share. Most diseases were grouped into several
clusters; in particular, the cancer cluster is tightly inter-
connected owing to the many genes associated with
multiple types of cancer. This has led to successful
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research using various molecular networks. Zhang et al.
(2011) proposed a disease network using the protein-
protein interaction (PPI) network [14], motivated by stu-
dies indicating the genes that share similar or the same
disease phenotypes tend to encode proteins that interact
with each other [15, 16]. Indeed, the Hermansky–Pudlak
syndrome [17] and Fanconi anemia [18] are known to be
caused by mutations affecting different, but interacting,
proteins. Lee et al. (2008) used the metabolic pathway
network, and hypothesized that diseases are associated if
they are linked to potentially correlated metabolic reac-
tions [19]. Paik et al. (2014) proposed network-based
disease–disease similarity analysis by focusing on topolo-
gical similarity, suggesting disease-pathological symp-
toms through protein interactions [20]. A number of
disease network studies have incorporated related meth-
ods [21–24].
Although our understanding of disease networks has
expanded by virtue of the growth in theories and techni-
cal tools in the past, there is some room for improve-
ment in the previous research. First, many works on
disease networks have not identified tight associations
for metabolic diseases. For cancer related diseases, a can-
cer cluster is successfully characterized and its associa-
tions to other diseases, including several diseases with a
strong predisposition to cancer (such as Fanconi Anemia
and Ataxia Telangiectasia), are well established because
many genes are associated with multiple types of cancer
(TP53, KRAS, ERBB2, NF1, etc.). However, for metabolic
diseases, they are underrepresented, do not appear to
form a distinct cluster, and have the fewest connections
to other diseases. This result is attributed to the lack of
information on genetic mutations associated with meta-
bolic disease. But in practice, metabolic diseases may not
really be so independent of one another, since certain
metabolic diseases such as diabetes mellitus and hypo-
glycemia [25] or dyslipidemia and amyotrophic lateral
sclerosis [26] often co-occur in the same individual and
one can sometimes be considered a significant risk fac-
tor for the presence of the other. In the meantime, one
can find another motivation for the research on meta-
bolic disease network when consulting the report on
prevalence statistics for diseases. A large proportion of
people suffer from metabolic disruptions and the inci-
dence rate is in trending upwards at the population level.
During the period 2003 to 2012, metabolic syndrome
prevalence in the United States was approximately,
18.0% among adults aged 20~39 years, 35.0% among
adults aged 40~59 years, and 46.7% among adults aged
60 years and above [27]. With respect to diabetes in par-
ticular, 9.3% of the U.S. population has been diagnosed
with diabetes, and 37% of U.S. adults aged 20 years or
older were pre-diabetic in 2009–2012 [28]. On the other
hand, the cancer incidence rate in 2011 was
approximately 3.2% of the population and has declined
year by year. The cancer death rate has also been declin-
ing by 1.5% per year for two decades. When comparing
the statistics of metabolic diseases with those of cancer
[29], one cannot lay less emphasis on the significance of
metabolic diseases. Despite awareness of the importance,
studies on the network analysis for metabolic diseases
have not been yet well established. From those perspec-
tives, it is of special interest to elucidate further the asso-
ciations among metabolic diseases.
Second, disease networks have not been of benefit to
medical research and practice yet, although they are
poised to play a big role at the cellular level. The major-
ity of the research on disease networks is still limited to
developing a methodology to construct the network even
when the approach makes use of sources of information
from disease-gene associations, the interactions of pro-
teins encoded by disease-related genes, or the metabolic
pathways of diseases. We conjecture that it is because
the research, in most cases, was issued and conducted
by biologists pursuing purely scientific findings. In the
perspective of physicians/clinicians/patients, however,
this practice may be regarded as somewhat unkind since
the results obtained from biology labs are too remote to
be useful in the face of the reality of practicing medicine
on patients. A doctor who is referencing a disease net-
work when he/she treats a patient diagnosed with a par-
ticular disease may want to know if a co-occurrence is
accidental or causal or if it increases the likelihood of
the development of other diseases. It would be more
convenient if the answer is given in the form of number,
something like a score or a probability value, for disease
co-occurrence. Unfortunately, most of the current dis-
ease networks do not provide quantified information
such as disease co-occurrence scores, instead presenting
a map of topologies between diseases. A recent study of
Paik et al. (2014) provides the comorbidity information
by comparing protein interaction-based disease network
and medical reports-based disease network [20]. It gives
a simple dichotomous information if two diseases are
comorbid or not.
To address the limitations discussed above, we suggest
a disease network model that provides quantified infor-
mation, scores or probabilities for co-occurring diseases.
To overcome sparse connectivity between metabolic dis-
eases, we introduce the notion of walk of graph theory.
The length of walk controls the range of protein-protein
interactions that we use for identification of disease-
disease associations. This idea is inspired by the defini-
tion of metabolic disease—the result of a genetic defect
which frequently causes a metabolic enzyme to be non-
expressed, inactive, or functionally compromised [30].
This implies that we may identify latent associations
between metabolic diseases if we search deeper into the
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PPI network. There may be hidden evidences that see-
mingly unrelated proteins interact somewhere in any of
metabolic pathways. We then propose a method for dis-
ease scoring. Scores are calculated based on graph-based
semi-supervised learning (SSL). The algorithm collects
the latent information spread over the disease network
to calculate scores. We validate the results of the pro-
posed method with comorbidity literatures providing
enrichment study for disease co-occurrence.
Results
Data for constructing disease networks
To construct a network of metabolic diseases, a list was
obtained from MeSH in 2017. The National Library of
Medicine has a controlled vocabulary thesaurus in the
form of a taxonomy. When considering up to the second
level of the taxonomy, there are 302 descriptors for
metabolic diseases out of the 4663 listed diseases.
On the other hand, disease-protein relationship and
protein-protein interactions data were obtained from the
eight existing interaction databases: 53,480 disease-
protein relationships between 2411 diseases and 7733
proteins, and 60,794 protein-protein interactions among
15,281 proteins, respectively. Based on Entrez gene and
MeSH, we have curated all relational information related
to metabolic diseases from multiple databases. The pre-
sence or absence of disease-protein relation was estab-
lished to produce a binary disease vector. Table 1
summarizes the data sources. Of 302 metabolic diseases,
only 181 have at least one disease-protein relationship,
therefore, the size (the number of nodes) of our disease
network was set to 181. (Additional file 1: Table A1 in
Appendix A provides a full list of the 181 diseases.) The
size of the PPI network is 15,281. The configuration of
the two networks will be described as the upper and
lower layers in Fig. 5a.
Results for disease networks from the PPI network
The 181 metabolic diseases are represented as 15,281
dimensional vectors, where a disease vector is composed
of binary attributes, each of which stands for presence
(‘1’) or absence (‘0’) of the association with a particular
protein as in Fig. 6. A disease network is built by calcu-
lating associations between disease vectors. Cosine dis-
tance is employed and is fed into the Gaussian similarity
function (1): cosine distance is defined as dist (xi, xj) = 1
− ( xi · xj)/(‖ xi‖ · ‖ xj‖), where dist (xi, xj) is transformed
to similarity using cosine distance between xi and xj, ‘∙’
indicates the vector dot product, and ‖x‖ is the length of
vector x.
A disease vector for metabolic diseases is sparse since
only a few disease-protein associations are known. This
implies that the resulting disease network has sparse
connectivity as well: the density of the matrix for
disease-disease association is only 1.10%. See Fig. 1. Note
that this network corresponds to PPI(0) by the defini-
tions in Methods section. In Fig. 1, the entry represents
the counted number for disease-disease associations.
The matrix connectivity increases as q increase. The
heat-maps for disease-disease associations get denser as
the step size q increases. The density reaches 26.87% in
PPI(3). The results show that we can widen the range of
association of a disease (when there is only little infor-
mation available) by applying the notion of q-step on the
PPI network. And further, we can infer associations for
most diseases and for rare diseases as well with the
resulting disease network.
Figure 2 presents a toy demonstration for the pro-
posed disease network vs. the existing one by Goh
Table 1 Data for diseases, disease-protein relationships, and protein-protein interactions, and literature for comorbidity analysis: the
number in parentheses indicates the amount of data originating from the respective sources. See also Additional file 1: Appendix A
and C
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et al.’s. The disease network is composed of eight metabolic
diseases such as hyperlipoproteinemia, homocystinuria,
maple syrup urine disease, pyruvate dehydrogenase defi-
ciency, lipodystrophy, insulin resistance, Fanconi syndrome,
and congenital hyperinsulinism. The dotted line indicates
the edge by Goh et al.’s: there is only a single edge connect-
ing two diseases and the rest are disconnected. In contrast,
in PPI(integrated) disease network (a network piling up PPI(0)
up to PPI(3)), the diseases are all connected, and the con-
nection between the nodes is large with various connection
strengths. The width of an edge is proportional to the num-
ber of shared proteins. These are shown in grey solid lines
in Fig. 2. The comparison results show that we are now
able to make inferences about most diseases (including rare
diseases) based on these richer connections of the disease
network. Additional file 1: Fig. B1 in Appendix B provides a
full network comparison. (The Matlab source code is avail-
able in Additional file 2: ‘NetworkConstruction.m’.)
Results for disease scoring
Enrichment with comorbidity study
To validate the proposed method as reliable in real med-
ical/clinical practice, we adopted data from the literature
of a comorbidity study as an independent source of
information for this test. Comorbidity measures the pre-
sence of one or more additional diseases (or disorders)
co-occurring with a primary disease or the effects of
such additional diseases. The sources of information,
used by the researchers and scientists working on the
question of comorbidity, are case histories [31, 32], hos-
pital records of patients [33] and other medical docu-
mentation kept by family doctors, or insurance
companies [34]. Therefore, data in the literature from
comorbidity studies are mainly based on the clinical
experience and qualifications of the physicians carrying
out clinical, instrumental, and laboratory-confirmed
diagnoses. In total, 62 pairs of 55 comorbid diseases
Fig. 1 Changes in network density by a q-step walk on the PPI network: The amount of connections for disease-disease association increases as
the step size q increases. With rich connections among diseases, the chances of having inferences for most diseases, including rare diseases, are
increased because it enables us to use the information propagated from other diseases through the connections
Fig. 2 Disease network comparison: A small subset of diseases belonging to the metabolic diseases category in MeSH is selected. The nodes in
the graph represent the eight selected diseases, and the width of an edge indicates connection strength proportional to the number of shared
proteins between two diseases. In Goh et al.’s approach, there is only a single edge connecting two disease nodes, while the remaining six are
disconnected. In contrast, in PPI(0~q), all eight disease nodes are connected, and each has a high degree of node connectivity with various
connection strengths
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were obtained from a literature survey. See the last col-
umn of Table 1. The full list of the comorbidity litera-
ture used in this study is provided in Table C1, and the
references are provided in Additional file 1: Appendix C.
Comparative experiments for scoring
The proposed SSL based scoring method (in Methods
section) was applied to PPI(q) ‘s, hypothesizing that our
extended disease networks will provide improved scoring
as compared to the existing disease network produced
by Goh et al. Note that Goh et al.’s approach coincides
with that of our PPI(0) network. In order to obtain a ran-
dom control as a reference point, we created a rando-
mized network; we shuffled disease-disease associations
while keeping both the number of connected nodes and
the degree of a node the same as those of PPI(integrated),
and projected it onto a disease network. The loss-
smoothness tradeoff parameter μ in (5) was set to a large
number (μ = 100). From the published comorbidity stu-
dies, 55 out of 181 diseases were able to obtain labels in
our SSL scoring model. For instance, by setting the label
of a disease on ‘ yl = 1 ’, while keeping unchanged the
labels of the remaining 180 diseases as ‘ yu = 0 ’, we
obtained the predicted score for identifying the comor-
bid diseases with the given disease. The experiment was
repeated 55 times and the performance was measured
by AUC (the area under the receiver operating charac-
teristic curve) [35]. The AUC was obtained by compar-
ing predictive value f in (5) and PubMed Literatures:
presence (‘1’) or absence (‘0’) of PubMed literatures. It is
used as a standard for disease association and comorbid-
ity disease.
The AUC performances for the disease networks are
summarized in Fig. 3. The randomized disease network
produces an AUC of 0.5, which is only equivalent to the
performance by random guessing. However, PPI(0) lifts
the performance up to 0.69. Thereafter, the performance
of the disease network continuously increases as the step
size q increases up to q = 3: PPI(0) < PPI(1) < PPI(2) <
PPI(3). Given these results, it is plausible that the more
connected a disease network, the higher the AUC per-
formance will be. After q = 3, however, the performance
stayed unchanged till q = 6, then begins to degrade. We
conjectured that the complexity of PPI(3), in terms of
Fig. 3 AUC comparison from q = 0 to 10 for integrated networks: PPI(0~q). The experiment was repeated 55 times, and the average AUC value
with the standard deviation is presented as a circle with an error bar. PPI(0), PPI(1), PPI(2), and PPI(3) are individual disease networks constructed as
described in Methods section. PPI(0~q) s are integrated networks from Eq. (6). PPI(0) corresponds to the existing disease network suggested by Goh
et al. [21]. A randomized network is added to our experiment to obtain a reference performance. The best performance was achieved by PPI(0~3),
and p-values of the pairwise t-tests are shown in the bottom of the plot
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network connectivity, is enough to draw most of infor-
mation in data, therefore more complication may not be
needed. Additional file 1: Fig. D1 in Appendix D shows
performance of the individual networks. On the other
hand, it is interesting to observe that combining PPI(q)
to PPI(q + 1) (q = 0, 1, 2) further increases the AUC per-
formance. PPI(0~1) is an integrated network piling up
PPI(0) onto PPI(1), and PPI(0~2) is similarly constructed.
This pattern of improvement ends with PPI(0~3), result-
ing in an AUC of 0.72. The further integration did not
make significant improvement in performance, so it was
decided as our best network. The p-values of the pair-
wise t-test (Additional file 1: Table D1 in Appendix D)
demonstrate the statistical significance of the improved
performance of PPI(0~3) over the others. Additional
experiments were conducted to verify the performance
instead of leave-one-out. 5-fold cross validation was per-
formed for three disease groups: metabolic diseases, neo-
plasms, and nervous system diseases. The experiment
was repeated ten times, and for each of them, 5CV
was conducted after random permutation of data. The
results were summarized in an Additional file 1:
Appendix E.
Discussion
Implication of the probabilities of the associated diseases
Figure 4 depicts a typical example of the proposed scor-
ing results with the probabilistic transfer function (6).
Diabetes mellitus type II (T2DM) was set as the labeled
(target) disease, and then the probability values for asso-
ciation with the remaining 180 diseases were obtained
from the integrated network, PPI(0~3). The solid line in
the figure stands for the probability values of the 180
diseases. The open circles on the line correspond to the
diseases comorbid with T2DM evidenced by the litera-
ture. The below shows the clinical implications for some
of the marked comorbid diseases observed in the litera-
ture. More evidences can be found in Additional file 1:
Appendix F.
High in insulin resistance[a] and hyperinsulinism[b]
T2DM is preceded or accompanied by an elevated adip-
osity that causes insulin resistance [36]. Insulin resis-
tance causes hyperinsulinemia to maintain normal
glucose levels. When the pancreas cannot sustain hyper-
insulinemia to overcome insulin resistance, pre-diabetes
or T2DM ensues [37].
High in lactic acidosis[c]
Lactic acidosis is caused by accumulation of lactic acid
more rapidly than it can be metabolized. It may occur
spontaneously or in association with diseases such as
T2DM, leukemia, or liver failure [38].
High in diabetic ketoacidosis[d] vs. low in acidosis[e]
Presence of Diabetic ketoacidosis has been increasingly
recognized in patients with T2DM, and a newer entity
called ketosis-prone diabetes is also commonly recog-
nized [39, 40]. Diabetic ketoacidosis in patients with
T2DM tends to present with a less severe acidosis and
patients are more likely to have normal potassium levels
[41–43].
Fig. 4 Probabilities of the diseases associated with T2DM: The solid line represents the probability values of the 180 diseases. Shown on the line
with open circles are the locations of 13 diseases comorbid with diabetes mellitus type II. The probability values support the knowledge based
on real medical practice and vice versa
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Conclusion
In this study, we proposed two novel methods: the
method of disease network construction by extracting
latent information from different depths of layers of the
PPI network and the method of disease scoring based on
SSL by collecting the latent information spread over the
network. To examine whether the proposed method for
disease co-occurrence provides predictions within rea-
sonable bounds in practice, we investigated pairs of
comorbid diseases that were reported in the literature
and compared them with the obtained scores. The result
was promising; the scoring results appear concordant
with conventional comorbidity studies.
There are some noteworthy features of the present
study: (a) Despite great progress in research on disease
networks, there are still barriers for physicians to use it
in practice: a disease network has been little more than a
map of topologies between diseases. It is inconvenient to
deduce the co-occurrence of the associated diseases, and
they do not have enough confidence to put it into action
when practicing a patient. From this point of view, this
study suggests a streamlined methodology with biologi-
cally driven knowledge—the protein-protein interaction
data— and the scores for disease co-occurrences. This
will eventually assist physicians in adopting smarter stra-
tegies earlier to aid them in tackling the numerous intri-
cacies inherent to the treatment of diseases.
(b) The proposed method of constructing a disease
network is an unprecedented and systematic approach.
Previous work identifies disease-disease associations
based on the gene that diseases share [13], based on the
gene encoding the protein that interacts with the protein
encoded by other disease genes [14], or based on shared
metabolites and correlated metabolic reactions [19]. The
present study provides a framework embracing the pre-
vious work: Goh et al. (2007)‘s is analogous to our
PPI(0), Zhang et al. (2011)‘s to PPI(0~1), Lee et al.
(2008)‘s to PPI(q) where q is arbitrary depending on the
size of metabolic pathway, and Paik et al. (2014)‘s to
PPI(q) where q is 0 and 1. With our methodology, it
becomes simple to expand or shrink the reference
ranges of the PPI network—just adjust the step size q of
walk! With the ongoing growth in study for the comple-
teness of the PPI network such as [44] and the refer-
ences therein, we expect that the proposed methodology
on how to construct a disease network from PPI will
further power the disease mechanism research.
(c) An algorithm for disease scoring must be able to
deal with the circumstance that only limited labeled data
are provided because a patient will provide only a few
pieces of information on one or two diseases that he/she
has contracted. SSL can handle these situations, and this
trait has inspired us to develop a scoring algorithm
based on SSL.
In this study, we have only focused on the connectivity
of diseases via genes without considering they are essen-
tial or redundant. We could not disregard a gene even if
it is regarded as redundant because it can be used as a
link to reach other diseases. We provided a typical case
about how a disease is linked to other diseases, and
therein, which gene turns out to be important (essential)
for the connection (See Additional file 1: Appendix G).
We note that the current study is motivated by and
developed for metabolic diseases that are known to be
the most disconnected class for most human disease
networks. Extension of this methodology to the whole
set of human diseases should be attempted next. We
added some preliminary results for other categories of
disease to Additional file 1: Appendix H. Another exten-
sion may be developed by incorporating diverse data
sources to our method. Particularly, if updating the
translational disease network with cleaner and higher
quality of data [45], we expect that it will be upgraded to
be more reliable and accurate.
Methods
The translational disease networks consist of two meth-
ods: (a) a method of constructing a disease network based
on protein-protein interaction data and (b) a network-
based scoring method for calculating the probabilities of
disease co-occurrence when a specific disease is given.
The resulting disease network from the first becomes the
base on which the second works. See (a) and (b) in Fig. 5.
Disease networks by q-step walks on the PPI network
The disease network is a graph, G(V,W), that represents
the associations between pairs of diseases by assigning a
weight to the edge connecting two diseases. In the net-
work, the node V denotes diseases and the weight W
denotes similarity between the sequences of proteins
that two diseases commonly share. In the proposed
method, the notion of commonly shared proteins is
expanded by applying the walk (or path) of graph theory
to the PPI network. The step size of walk on the PPI
network determines the number of shared proteins. On
a graph, a ‘walk’ starting at node vA and ending at node
vB, is represented as (vA→ v1→…→ vn→ vB). The
edges connect the successive nodes in a walk. Let us
define a ‘q-step walk’ as a walk of length q, which travels
q edges departing from vA for vB. In a conventional
approach for constructing a disease network, the two
diseases are defined as associated only if they are known
to share same proteins. In Fig. 5a, DB and DC share
protein P1, therefore they are considered as associated.
Figure 6a rephrases this in disease-protein vector repre-
sentation, and we see that there exists no other disease
association than a single one between DB and DC. In
terms of q-step walk, it corresponds to the case of q = 0.
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However, if the notion of q-step walk is applied to the
PPI network, disease associations can be further
expanded. Consider DA in Fig. 5a which is known to be
related to two proteins P2 and P3. And it is not asso-
ciated with any of diseases in 0-step walk. An 1-step
walk departing from those proteins reaches P1 and P4,
respectively, (see Fig. 5a), and produces a different
disease-protein vector (see Fig. 6b). Then, it now can be
associated with DB and DC. Similarly, a 2-step walk
( P3→ P4→ P5) or a 3-step walk (P3→ P4→ P5→ P6)
makes expanded associations with other diseases, which
are described in Fig. 6c and d.
Applying different q-step walk to the PPI network, a
disease network can be differently constructed, and is
denoted as PPI(q). The following lists general definitions
of PPI(q) ‘s where q = 0, 1, 2, 3. The disease network by
q-step walks on PPI network is a graph PPI(q) =G(V,
W(q)), where W(q) is the similarity after applying q-step
walks. (Note that the initial network, PPI(0), is original
disease network G(V,W)). Consider two diseases, Dis-
ease I and Disease II, assuming that the former is known
to be associated with protein PI and the latter with PII.
The step-by-step process of q-step walk is described in
detail in Additional file 1: Appendix I.
▪ PPI(0): The two diseases are defined as associated only
if PI and PII are identical (PI≡ PII)—the disease
network by 0-step walk.
▪ PPI(1): An association between the two diseases is
defined when the proteins are known to interact (PI~PII
where ‘~’ stands for interaction)— the disease network
by 1-step walk.
▪ PPI(2): Let us introduce an extra protein PIII which
interacts with the two disease proteins (PIII~PI,
PIII~PII). Through bypassing the medium protein, PI→
PIII→ PII and vice versa, the two diseases are related—
the disease network by 2-step walk.
▪ PPI(3): Similarly, a 3-step walk on the PPI
network, PI→ PIII→ PIV→ PII, can bridge the two
diseases via two medium proteins, PIII and PIV—the
disease network by 3-step walk.
One may further develop PPI(q) ‘s by increasing the
walk length q. As q increases, more associations can be
Fig. 5 The proposed model: a a method of constructing a disease network based on a q-step walk on the protein-protein interaction (PPI)
network and b a scoring model for calculating the scores of disease co-occurrence when a specific disease is given
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found among diseases, and the density of the disease
network increases. It is conjectured that a network of a
larger step size is relatively less informative because of
loss of information while touring around the network.
On the contrary, a small step size q provides a good
quality of associations between diseases but it may result
in a disconnected disease network where many of the
diseases remain isolated (or dangled), and is described in
this paper as a drawback of the status quo approaches
[13, 14]. Note that disease associations based on the
above definitions are reciprocal; hence, a resulting dis-
ease network, PPI(q), is symmetric.
A scoring model for co-occurring diseases
Once a disease network is obtained, a person who has
caught/contracted a particular disease may wish to be
informed regarding how likely he/she is to be exposed to
other diseases. Hypothesizing that at least one disease is
known, the proposed scoring method calculates probabil-
ities for the associated diseases.
Scoring algorithm
Let us define disease scoring as a function that quantifies
the degree of commitment of the associated diseases
when one or a few diseases are given. To embody
scoring in a disease network, PPI(q), we employ the con-
ventional settings for the graph-based semi-supervised
learning (graph-based SSL) classification and modify it to
be suitable for our scoring problem. SSL has attracted the
interests of many researchers in areas where labeled data
are a few but unlabeled data are abundant [5, 46–52]. And
it has been reported that SSL successfully improves classi-
fication performance by supporting classifiers with unla-
beled data [5]. The motivation of SSL is appealing for our
problem because it will be typical for a patient to have
contracted one or a few diseases (labeled data) but not the
rest of the diseases (unlabeled data). To implement an SSL
based scoring algorithm one has to perceive the difference
between classification and scoring. In a (binary) classifi-
cation problem, the labels given to a classifier are bin-
ary (+ 1 or − 1), and the resulting prediction is made by
the way that each of the unlabeled data are assigned to
either one class (+ 1) or the other (− 1). On the con-
trary, in a scoring problem, unary labels (+ 1) are given
to a scorer, and the resulting predictions are scores that
prioritize the unlabeled data for the given labels. In the
proposed method, it also outputs the corresponding
probability values. Figure 5b schematically describes
our graph-based SSL scoring method, and the following
paragraphs explain the details.
Fig. 6 Associated diseases of DA by q-step walks on the PPI network in the case of a q=0, b q=1, c q=2 and d q=3
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Consider a graph G = (V,W) with node V correspond-
ing to the n(=nl + nu) data points from labeled set SL ¼ f
ðxi; yiÞnli¼1g and unlabeled set SU ¼ fðxiÞni¼nlþ1g . In the
proposed SSL based scoring problem, the nl nodes are
set to a unary label yl ∈ {1} while the unlabeled nu nodes
are set to zero (yu ∈ {0}). The task is to assign scores f
T
u
¼ ð f nlþ1;…; f nÞT on nodes VU. To compute a real-
valued scoring function f :V→ℝ on G, one strategy is to
let the label information propagate to the unlabeled
nodes through edges W. The edge weight wij between
the two nodes xi and xj can take a value of 0 or 1 in the
simplest case. Usually, dist (xi, xj) between xi and xj is
transformed to similarity using Gaussian
wij ¼ exp




where i~j indicates that the two nodes are connected.
The connection strength is encoded in wij of a similarity
matrix W, and a large value of wij represents more simi-
larity between the two nodes. Assuming that fi should be
close to the given label yi in labeled nodes—loss condi-
tion, and overall, fi should not be too different from the fj
of adjacent nodes—smoothness condition, one can




H fð Þ ¼ f −yð ÞT f −yð Þ þ μ f TLf ð2Þ
where y ¼ ½y1;…; ynl ; 0;…; 0T : The matrix L known as
the graph Laplacian matrix, is defined as L =D −W
where D = diag (di), di =
X
j
wij . The user parameter μ
trades off loss (the first term of H(.)) and smoothness
(the second term). The solution of this problem
becomes
f ¼ I þ μLð Þ−1y ð3Þ
One may compute the scores for the unlabeled nodes
explicitly in a block-wise representation of the similarity
matrix W = [Wll Wlu | Wul Wuu]. Let us represent (3) as





¼ I þ μ Dll−Wllð Þ −μWlu






Then, one can simplify (4) by substituting fl = yl and
yu = 0, and by writing it in terms of fu, we obtain the
scores for the unlabeled nodes,
f u ¼ μ I þ μ Duu−Wuuð Þf g−1Wulyl: ð5Þ
On a network of diseases, by setting yl = 1 to the nodes
for the contracted diseases, one can obtain scores fu for
the rest of diseases from (5).
Probability calculation
After obtaining scores from a disease network, the next
step is to transform the scores to probability values of
disease co-occurrence. The resulting scores fu from (5)
is unique and satisfies 0 < fu < 1 . After normalizing the
overall fu ‘s, the scores can be associated with probability
values as below
Prob ujlð Þ ¼ 1
1þ exp− f u=σ f ð6Þ
where σf is a scale parameter. Given primary diseases (l),
the output value of (6) measures probability values of
disease co-occurrence for other diseases (u). One can
refer to the values when attempting to figure out the
secondary or tertiary diseases to the given one.
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